论文部分内容阅读
方法 :应用酶联免疫吸附法 ( EL ISA )测定 3 8例原发性肝癌患者 ( PHC)和 2 0例健康对照者血清 s VCAM-1。结果 :原发性肝癌患者血清 s VCAM-1水平显著高于健康对照组 ( P<0 .0 1) ;临床不同时期血清 SVCAM-1存在着显著性差异。结论 :s VCAM-1参与了原发性肝癌的发病过程 ,它可为其病情变化提供重要的临床参考。
Methods : VCAM-1 was detected by enzyme linked immunosorbent assay (EL ISA) in 38 patients with primary liver cancer (PHC) and 20 healthy controls. Results: The serum sVCAM-1 level in patients with primary liver cancer was significantly higher than that in the healthy control group (P<0.01). There was a significant difference in serum SVCAM-1 levels at different clinical stages. Conclusion :S VCAM-1 is involved in the pathogenesis of primary liver cancer. It can provide an important clinical reference for the change of its condition.